Rise in Prevalence of Obesity in Youth, Adults With T1DM Seen From 2008 to 2023
By Elana Gotkine HealthDay Reporter
FRIDAY, April 4, 2025 -- From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with type 1 diabetes, and glucagon-like peptide 1 receptor agonist (GLP-1 RA) prescriptions also increased for this group over time, according to a study published online March 3 in Diabetes, Obesity and Metabolism.
Yunwen Xu, Ph.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues characterized trends in obesity and prescriptions for GLP-1 RAs across body mass index (BMI) categories among U.S. patients with type 1 diabetes (youth [2 to 19 years] and adults [20 years and older]).
The researchers found that from 2008-2011 to 2020-2023, the prevalence of obesity increased from 18.1 to 26.0 percent among youth with type 1 diabetes and from 30.5 to 38.1 percent for adults with type 1 diabetes. Black and Hispanic youth and adults had the highest obesity rates; over time, racial and ethnic disparities persisted. Across all BMI categories, GLP-1 RA prescriptions increased significantly during the last 15-year period in a dose-response manner among youth and adults with type 1 diabetes.
"Obesity and GLP-1 RA prescriptions across different BMI categories have surged over the last 15-year period in a large and diverse U.S. population of youth and adults with type 1 diabetes," the authors write. "Our findings underscore the urgent need for safety and efficacy data on GLP-1 RAs and clinical guidelines for obesity management among the type 1 diabetes population."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 -- After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among...
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 -- The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.